Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

By Nikita Chaurasia  | Date: 2021-04-06

Zydus seeks DCGI approval for PegIFN drug to treat COVID-19 patients

Indian pharmaceutical company Zydus Cadila is reportedly seeking approval from DCGI (Drug Controller General of India) for its PegIFN (Pegylated Interferon Alpha-2b), a hepatitis C drug, to treat COVID-19 patients, after its third phase of clinical trials displayed promising outcome.

The pharmaceutical firm said that in its Phase 3 trials, more than 91.15% of patients administered with PegIFN PegiHepTM, had an RT-PCR negative result by the seventh day, in comparison to 78.90% of patients treated with SOC (standard of care) arm.

In the case of moderate COVID-19 patients, the medication decreased the period of additional oxygen from 84 hours to 56 hours. This shows that it was able to manage respiratory distress and failure, which has been one of the most difficult aspects of managing COVID-19, the company added.

It is worth noting that the drug has a well-established record of safety, with several doses being given to chronic hepatitis B and C patients for several years.

Aging decreases the ability of the body to generate Interferon Alpha which helps in responding to viral infections, further increasing the risk of death among elderly individuals. Pegylated Interferon Alpha 2b, provided at an early stage of the infection, can compensate for this deficiency and speed up recovery.

The preliminary findings suggest that, if given early, PegIFN can help in faster recovery of patients and prevent many of the problems seen in later stages of the disease. Since it is a single-dose regimen, the treatment would be less difficult and more affordable, Zydus said.

Dr. Sharvil Patel, Managing Director at Cadila Healthcare Ltd., reportedly said that they are motivated by the Phase III results of the PegIFN study which has shown the potential to decrease the impact of the virus when given in the early stage of the disease.

In addition to performing a Phase-II trial in Mexico, the company is collaborating with the USFDA on Pegylated Interferon clinical trials in the United States, sources with relevant information cited.

Source Credit –

https://www.businesstoday.in/current/corporate/zydus-covid-19-drug-shows-promise-phase-3-trials-seeks-dcgi-nod/story/435729.html

 

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More >>

More News By Nikita Chaurasia

Pacific Island pushes Japan to delay wastewater release from Fukushima

Pacific Island pushes Japan to delay wastewater release from Fukushima

By Nikita Chaurasia

Pacific Island nations have reportedly pushed Japan to postpone the release of Fukushima nuclear power plant wastewater due to concerns that it may pollute fishing grounds. An appeal was made on Wednesday when Japan announced that treated sewage f...

Activist groups take Danone to court over excessive use of plastics

Activist groups take Danone to court over excessive use of plastics

By Nikita Chaurasia

Danone, the French bottled water and yogurt firm, is reportedly being sued in court by three environmental activists’ groups for failing to cut its plastic footprint significantly. According to the groups, the maker of Evian and Volvic miner...

Bosch expands security with dashcams designed for rideshare drivers

Bosch expands security with dashcams designed for rideshare drivers

By Nikita Chaurasia

Bosch, the German technology company, has reportedly expanded its security footprint in the ridesharing market with the launch of its latest security dashcams. At CES 2023, Las Vegas, the German tech firm unveiled a new integrated smart camera on ...

Australia: PM Albanese denies potential $450M payout to Rio Tinto

Australia: PM Albanese denies potential $450M payout to Rio Tinto

By Nikita Chaurasia

Australia's Prime Minister Anthony Albanese has reportedly denied rumors that Rio Tinto and its partners could receive a $450 million settlement for the Gladstone power station, which would bring the total compensation for the coal price limit to...

UK: Firms still struggle with post-Brexit trading and red tape

UK: Firms still struggle with post-Brexit trading and red tape

By Nikita Chaurasia

Businesses in the UK are still reportedly grappling after two years following the beginning of post-Brexit trading, as suggested by a new report. According to the British Chambers of Commerce (BCC), firms are still battling increased red tape and ...